Maker of Panadol - Haleon launches as an independent company, completing its demerger from GSK

MAKER OF PANADOL – HALEON LAUNCHES AS AN INDEPENDENT COMPANY, COMPLETING ITS DEMERGER FROM GSK

JULY 19, 2022 @ 11.32AM

Haleon aims to empower 50 million people a year by 2025 to be more included in opportunities for better everyday health.

Today, Haleon (LSE/NYSE: HLN) launches as an independent company 100% focused on consumer health, completing its demerger from GSK. The newly listed business is driven by its purpose to deliver better everyday health with humanity.

Trading commenced on Monday on the London Stock Exchange (LSE), with Brian McNamara, CEO of Haleon, leading the opening ceremony to signal the start of trading. Trading on the New York Stock Exchange (NYSE) is set to follow, and a similar market-opening event will take place on Wednesday 20 July 2022.

Haleon has a world-class portfolio of brands including Panadol, Sensodyne and Scott’s, and will continue to develop category leading brands that address real consumer health needs, while focusing on future innovation across its entire portfolio.

With an increased consumer focus on health and wellness, an ageing global population, an emerging middle class in high-growth economies, growing self-care in the face of increased pressure on public healthcare systems and sizeable unmet consumer needs, Haleon has launched at a time when the consumer healthcare market is set for expansion (expected to be at a rate of 3-4% per annum over the medium-term). Haleon expects to deliver medium-term annual organic revenue growth of 4-6%.

Despite huge improvements in medicine, data and technology, everyday health remains elusive for too many people. Haleon aims to change this through a two-pronged approach. First, by working to remove barriers to better everyday health, and second, by aiming to empower 50 million people a year by 2025 to be more included in opportunities for better everyday health.

The company’s competitive advantage lies in its ability to blend deep human understanding and trusted science in the products it creates. Haleon is further distinguished by leading consumer healthcare-focused scientific capabilities, a well-developed organisational understanding of human health behaviours, strong capabilities in brand building, innovation and digital commerce and a powerful route-to-market.

The brands within the Haleon portfolio have been providing treatment and improving the quality of life for millions of consumers across the globe for decades. They have also been trusted, recognised, and recommended by healthcare professionals across multiple markets.

Brian McNamara, Chief Executive Officer, Haleon, said: “This is a significant milestone for Haleon. guided by our clear purpose and with a world class portfolio of brands that people know and trust, we stand ready to help address consumer needs and make better everyday health more achievable, inclusive and sustainable.

“Consumer health has never been more important than it is today, and I am delighted that Haleon, as an independent company, is ready to pursue our ambitions. Today follows a huge amount of effort, planning and collaboration by our dedicated colleagues all around the world.”

Bryan Wong, General Manager, Malaysia, Singapore and Brunei (MSB), Haleon, said: “As a category leader across pain relief, oral care, and wellness in Malaysia, we will continue to promote the importance of self-care and maintain a world-class portfolio of loved and trusted brands. As people become more aware of the various health conditions such as lack of daily nutrients, or oral and gum problems, and have an ongoing quest to live healthier and longer lives, we would like to make everyday health more achievable and empower people to manage their self-care. We are also looking forward to working with healthcare professionals and retailers to make everyday health more inclusive, and more sustainable for everyone in Malaysia.”

​​​MAKER OF PANADOL – HALEON LAUNCHES AS AN INDEPENDENT COMPANY, COMPLETING ITS DEMERGER FROM GSK

MAKER OF PANADOL – HALEON LAUNCHES AS AN INDEPENDENT COMPANY, COMPLETING ITS DEMERGER FROM GSK